Scleroderma target discovery

Scleroderma target discovery - Scleroderma target discovery

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41288

Enrollment

Registered

2013-11-04

Start date

2014-01-02

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scleroderma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Diagnosed with diffuse cutaneous systemic scleroderma according to ACR, Leroy criteria or ACR/EULAR criteria. - Duration should be equal or less than 18 months since the first non-Raynaud symptom - Presence of autoantibodies against RNA polymerase III, topoisomerase (Scl-70), antifibrillarine or PMScl. - Preferably diagnosed recently and no/limited confounding effect of immunosuppressive therapy

Exclusion criteria

Exclusion criteria: - Individuals who fail to meet the inclusion criteria.

Design outcomes

Primary

Measure	Time frame
Genes that upon knockdown interfere with SSc-related phenotypes in human fibroblasts	—

Secondary

Measure	Time frame
Nvt	—

Countries

Netherlands

Outcome results